Regencell Bioscience (NASDAQ:RGC) Shares Gap Down – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares gapped down prior to trading on Monday . The stock had previously closed at $21.16, but opened at $20.00. Regencell Bioscience shares last traded at $23.18, with a volume of 146,804 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The stock has a 50-day moving average of $15.57.

Institutional Investors Weigh In On Regencell Bioscience

Several hedge funds have recently added to or reduced their stakes in the business. Greenfield Savings Bank acquired a new stake in Regencell Bioscience during the second quarter worth about $187,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience during the 2nd quarter valued at approximately $222,000. Geode Capital Management LLC lifted its stake in shares of Regencell Bioscience by 5,637.5% in the 2nd quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock valued at $6,664,000 after purchasing an additional 384,250 shares during the period. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience during the second quarter worth $1,701,000. Finally, BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience during the second quarter valued at $768,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.